Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development

Mark Throsby; Jan ter Meulen; Cecile Geuijen; Jaap Goudsmit; John de Kruif

doi:10.1586/14760584.6.2.183

Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development

Mark Throsby
, Jan ter Meulen
, Cecile Geuijen
, Jaap Goudsmit
, John de Kruif

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

Seasonal epidemics of West Nile virus (WNV) infection now occur throughout North America, causing clinical symptoms ranging from fever to encephalitis. There are no specific treatment options or licensed vaccines. Several classically developed vaccine candidates are being evaluated in clinical trials. However, questions of safety and/or immunogenicity may limit their usefulness. Mapping of human and murine antibody repertoires against the WNV envelope protein after WNV infection have revealed important insights into the protective immune response against the virus. This review will give an overview of vaccines under development and summarize current data on E-protein antigenicity that could aid in the design of next generation WNV vaccines

Original language	English
Pages (from-to)	183-191
Journal	Expert review of vaccines
Volume	6
Issue number	2
DOIs	https://doi.org/10.1586/14760584.6.2.183
Publication status	Published - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1586/14760584.6.2.183

Cite this

@article{bb9ceb08c37e483d9b77d2e682ceaec0,

title = "Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development",

abstract = "Seasonal epidemics of West Nile virus (WNV) infection now occur throughout North America, causing clinical symptoms ranging from fever to encephalitis. There are no specific treatment options or licensed vaccines. Several classically developed vaccine candidates are being evaluated in clinical trials. However, questions of safety and/or immunogenicity may limit their usefulness. Mapping of human and murine antibody repertoires against the WNV envelope protein after WNV infection have revealed important insights into the protective immune response against the virus. This review will give an overview of vaccines under development and summarize current data on E-protein antigenicity that could aid in the design of next generation WNV vaccines",

author = "Mark Throsby and \{ter Meulen\}, Jan and Cecile Geuijen and Jaap Goudsmit and \{de Kruif\}, John",

year = "2007",

doi = "10.1586/14760584.6.2.183",

language = "English",

volume = "6",

pages = "183--191",

journal = "Expert review of vaccines",

issn = "1476-0584",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development

AU - Throsby, Mark

AU - ter Meulen, Jan

AU - Geuijen, Cecile

AU - Goudsmit, Jaap

AU - de Kruif, John

PY - 2007

Y1 - 2007

N2 - Seasonal epidemics of West Nile virus (WNV) infection now occur throughout North America, causing clinical symptoms ranging from fever to encephalitis. There are no specific treatment options or licensed vaccines. Several classically developed vaccine candidates are being evaluated in clinical trials. However, questions of safety and/or immunogenicity may limit their usefulness. Mapping of human and murine antibody repertoires against the WNV envelope protein after WNV infection have revealed important insights into the protective immune response against the virus. This review will give an overview of vaccines under development and summarize current data on E-protein antigenicity that could aid in the design of next generation WNV vaccines

AB - Seasonal epidemics of West Nile virus (WNV) infection now occur throughout North America, causing clinical symptoms ranging from fever to encephalitis. There are no specific treatment options or licensed vaccines. Several classically developed vaccine candidates are being evaluated in clinical trials. However, questions of safety and/or immunogenicity may limit their usefulness. Mapping of human and murine antibody repertoires against the WNV envelope protein after WNV infection have revealed important insights into the protective immune response against the virus. This review will give an overview of vaccines under development and summarize current data on E-protein antigenicity that could aid in the design of next generation WNV vaccines

U2 - 10.1586/14760584.6.2.183

DO - 10.1586/14760584.6.2.183

M3 - Review article

C2 - 17408368

SN - 1476-0584

VL - 6

SP - 183

EP - 191

JO - Expert review of vaccines

JF - Expert review of vaccines

IS - 2

ER -

Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this